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To evaluate the sympathetic innervation of the female diabetic heart, resting heart rate and sympathetic tone were assessed in vivo,
and eﬀect of tyramine on spontaneous beating rate, norepinephrine atrial concentrations, uptake, and release were determined
in vitro in streptozotocin- (STZ-) treated rats and respective controls aged 3 months to 2 years. Resting bradycardia, decreased
sympathetic tone, deceleration of spontaneous beating rate, and slightly declining carrier-mediated, but preserved exocytotic
norepinephrine release from the atria were found in younger diabetic rats while the reactivity of the right atria to tyramine was
not aﬀected with age and disease duration. Diabetic two-year-old animals displayed symptoms of partial spontaneous recovery
including normoglycemia, increased plasma insulin concentrations, fully recovered sympathetic tone, but putative change, in
releasable norepinephrine tissue stores. Our data suggested that female diabetic heart exposed to long-lasting diabetic conditions
seems to be more resistant to alteration in sympathetic innervation than the male one.
1.Introduction
Cardiovascular autonomic neuropathy (CAN) represents the
most clinically important form of diabetic autonomic neu-
ropathy. CAN results from damage to the sympathetic and
parasympathetic innervation of the cardiovascular system,
anditistypicallymanifestedbyreducedheartratevariability,
exercise intolerance, orthostatic hypotension, and silent
myocardial ischemia [1]. Autonomic dysfunction manifested
by intracardiac sympathetic imbalance with predisposition
to arrhythmias has been proposed as a cause of the increased
incidence of sudden cardiac death in diabetic patients [2].
Although multiple data indicated an abnormal activity
of the sympathetic nervous system in both diabetic human
patients and animals with various experimental models of
diabetes, their results are contradictory showing decrease,
increase, or no change in plasma catecholamine levels,
cardiac norepinephrine content, release, or uptake [3, 4].
The regulation of norepinephrine tissue stores is very
complex involving control of expression and/or activity of
the key synthesizing enzyme tyrosine hydroxylase, cate-
cholamine exocytotic and nonexocytotic release, its uptake,
and metabolism [5–7]. The inconsistent results of studies
dealing with norepinephrine turnover in the tissues of
streptozotocin- (STZ-) diabetic animals were attributed
mostly to the duration and severity of diabetes [8].
Remarkably little attention has been paid to this issue
in female rats, although multiple lines of evidence suggest
considerably higher diabetes-related relative risk for serious
cardiovascularcomplicationsindiabeticwomenthaninmen
[9, 10]. Recently, we have reported an interesting feature of
STZ-induced model of diabetes in female rats: within one
year of the disease duration, a substantial number of STZ-
injected animals displayed symptoms of partial spontaneous
recovery with decreasing blood glucose concentrations and
increasing insulin levels in the plasma and pancreas [11].
However, despite this spontaneous improvement of the dia-
betic state, norepinephrine levels in the heart compartments
remained lower than in the age-matched controls 12 months
after the onset of the disease.2 Experimental Diabetes Research
The aim of the present study was to investigate how
diabetes aﬀects the content, release, and uptake of nore-
pinephrine in cardiac sympathetic nerves 1 to 22 months
after STZ administration (i.e., at the ages from 3 months to
2 years) in female rats with severe uncompensated diabetes,
in animals that displayed symptoms of partial spontaneous
recovery, and in the age-matched controls.
2.MaterialsandMethods
2.1. Animals. Wistar female rats purchased from VELAZ
( P r a g u e ,C z e c hR e p u b l i c )a tt h ea g eo f5 0d a y sw e r eu s e d .
The animals were housed ﬁve per cage and fed standard
laboratory chow with free access to drinking water. All
animals were left intact to adapt for 2 weeks before the
initiation of the study. All experiments were conducted in
accordance with the European Directive for the Protection of
Vertebrate Animals Used for Experimental and Other Scien-
tiﬁc Purposes (86/609/EU) and the relevant guidelines of the
Czech Ministry of Agriculture for scientiﬁc experimentation
on animals and were approved by the University Committee
for Experiments on Laboratory Animals. After adaptation,
rats (n = 270) were randomly divided into two groups:
160 animals were rendered diabetic by a single intravenous
injection of STZ (65mg/kg of the body weight) dissolved in
citrate buﬀer (pH 4.5), and 110 animals were injected with
vehicle serving as controls. Diabetes was veriﬁed by severe
hyperglycemia 48 hours after STZ administration. Blood
glucose levels were measured by glucose oxidase method
and checked bimonthly till the age of one year and then 22
months after the onset of the disease. About 30% (n = 46)
of diabetic rats died in the course of the study. The rats
were used for further experiments at 1, 2, 4, and 22 months
after the induction of diabetes or vehicle administration
and designated STZ1, STZ2, STZ4, and STZ22 and CONT1,
CONT2, CONT4, and CONT22, respectively.
2.2. Measurement of the Heart Rate. To estimate the tonic
inﬂuence of the cardiac sympathetic innervation on heart
rate, the animals were placed in a small chamber with
electrodes in the ﬂoor that were connected to an electro-
cardiograph (EKG Seiva Praktik, Prague, Czech Republic).
Animals were left to adapt for 20min, and then the resting
heart rate was measured ﬁve times in one-minute intervals.
The eﬀect of nonselective β-adrenergic receptor antagonist
metipranolol (2mg/kg b.w., i.p.) on heart rate was tested
afterpreviousadministration of atropine (4mg/kgb.w.,i.p.).
First, atropine was administered; rats were left to adapt
for 15min; their heart rates were measured ﬁve times,
and then metipranolol was injected, and heart rate was
measured again 5 times after 15min adaptation period. The
values presented in the results represent means of these
measurements.
2.3.GlucoseToleranceTests. Glucosetolerancetestswereper-
formed in 24-month-old diabetic and age-matched control
rats (n = 5). The rats were fasted from evening before and
anaesthetized with urethane 1.5g/kg b.w. Glucose 2g/kg b.w.
was administered intraperitoneally, and blood samples were
collected from the orbital sinus before and at 15, 30, 60, 90,
120, and 180min after the glucose challenge (Figure 2).
2.4. Determination of Norepinephrine and Insulin Tissue
Concentrations. Diabetic rats of all categories and their
respective controls were anaesthetized with ether, killed by
cervical dislocation, and exsanguinated. Blood was collected
on EDTA and centrifuged (1000×g, 10min, 4◦C). The
aspirated plasma was stored at −20◦Cf o rs u b s e q u e n td e t e r -
mination of insulin concentration. The dissected right and
left heart atria and pancreas were rinsed with ice-cold saline,
immediatelyfrozenondryice,andweighed.Norepinephrine
was extracted from the atria by homogenization in 10
volumes of 0.1mol/L HCl and subsequent centrifugation
(5000×g,20min,4◦C).Supernatantswerediluted1:10with
distilled water and stored at −70◦C until radioimmunoassay
(RIA). Norepinephrine concentrations in the tissue extracts
were measured by commercial diagnostic kits (IBL, Ham-
burg, Germany).
Pancreatic tissues were frozen, weighed, and homogeni-
zed at 4◦C in 10 volumes of acid-alcohol solution (75%
(vol/vol)ethanol,23.5%bidistilledwater,and1.5% (vol/vol)
10mol/L HCl). Homogenates were centrifuged (5000×g,
20min, 4◦C); the supernatants stored at −20◦C until RIA
for insulin measurements (kits LINCO Research, St. Charles,
Mo, USA).
2.5.Immunohistochemistry ofthePancreas. Fortheimmuno-
histochemical study, whole pancreata were ﬁxed by immer-
sion in 4% buﬀered formaldehyde, embedded in paraﬃn,
and cut to 5μm thick tissue sections. The endogenous
peroxidase activity was blocked by a solution composed of
hydrogen peroxide (1 volume) and methanol (50 volumes).
For detection of insulin, sections were incubated with poly-
clonal guinea pig anti-insulin (1:150; Dako, Carpinteria,
Calif, USA) for 12 hours at 4◦C. The secondary antibody
(incubationfor45minat37◦C)andavidin-biotinperoxidase
complex (45min, 37◦C) were applied, using the Novostain
Super ABC Universal Kit (Novocastra Laboratories Ltd.,
Newcastle upon Tyne, UK). Following the immunohisto-
chemistry, the background tissue was stained with Gill’s
haematoxylin (30s; Bio-Optica, Milano, Italy).
For the quantiﬁcation of insulin-positive cells, the vol-
ume fraction of insulin-positive cells within the pancreas
Vv(insulin, pancreas) was estimated in two CONT22, two
STZ1 and ﬁve STZ22 rats according to the following
equation:
Vv

insulin,pancreas

=
estV(insulin)
estV

pancreas
, (1)
where estV(insulin) is the estimated volume of cytoplasm of
cells stained with the insulin antibody, and estV(pancreas)
is the total volume of the pancreas. Each pancreas was cut
e x h a u s t i v e l yt oas e r i e so f5 - μm-thick histological sections
and every eighth section, was selected for quantiﬁcation,
using systematic uniform random sampling. After taking
calibrated micrographs, we assessed the area of the proﬁles
of insulin-positive cells and area of whole pancreatic tissueExperimental Diabetes Research 3
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Figure 1: Scheme of the superfusion experiments. One intervention per experiment was assessed.
using the stereological point-counting method, see the
following equation:
estA = a ·P, (2)
whereestAistheestimatedareaofproﬁlesofinsulin-positive
cells (or the whole pancreas, resp.), grid parameter a is
the area corresponding to one test point according to the
calibration, and P is the number of test points hitting the
insulin-positive cells (or the whole pancreas, resp.). The total
number of points counted for both insulin-positive cells as
well as the whole pancreas was at least 200 in each series
of sections. We used the Cavalieri principle for estimating
the volume estV(insulin) and the estV(pancreas), see the
following equation:
estV = T ·(A1 +A2 + ···+Am),( 3 )
where estV is the Cavalieri volume estimator, T = 0.040mm
is the distance between the two following selected sections,
Ai is the area of the insulin-positive cells (or the pancreas,
resp.) in the ith section, and m is the total number of
sections selected from the series. Stereological analysis was
done using the PointGrid module of the Ellipse software
(ViDiTo, Kosice, Slovakia).
2.6. Evaluation of Tyramine-Induced Positive Chronotropic
Eﬀect. The chronotropic experiments were performed 1, 2,
4, and 22 months after STZ or citrate buﬀer application.
Animals were anaesthetized with intraperitoneal injection
of urethane (1.5g/kg body weight) 10min after having
received heparin (500U, i.p.), and their hearts were quickly
excised. The right atria were snipped and placed into an
experimental chamber with Tyrode solution. The solution
was maintained at 32◦C and continuously aerated with
clear oxygen. The action potentials of the preparation
were recorded with an extracellular electrode, which was
attached to the preparation and with the second electrode
freely placed in the solution without any contact with
the preparation. Potentials were recorded by means of the
laboratory system Biopac (Biopac Systems, Inc.; Goleta,
CA, USA). After stabilization period (at least 30min), the
chronotropic eﬀect of tyramine was tested. The cumulative
doses of tyramine (concentrations from 10−7 to 10−4 mol/L)
were administrated at two-minute intervals. The potentials
were recorded at the end of two-minute interval, and
higher concentration of tyramine was added immediately
afterwards. The heart rate was calculated as the average of
ﬁve randomly chosen values from each recording.
2.7. Norepinephrine Release from the Atria. Control and
diabetic rats were anaesthetized with ether and decapitated.
The hearts were rapidly excised and placed into ice-cold
Tyrode solution containing 1μmol/L monoaminooxidase
inhibitor pargyline. Both atria were dissected, sliced into
pieces (thickness 300μm) by McIllwain tissue chopper, and
pooled in a beaker containing oxygenated Tyrode solution
with pargyline. Tissue slices (approx. 50–100mg of atrial
tissue) were transferred into 12 parallelly perfused 0.5mL
perfusion chambers. Tissues were superfused at a rate of
∼0.1mL/min with oxygenated Tyrode solution with par-
gyline. All perfusion experiments were performed at 37◦C.
After40minequilibrationperiod,four20minfractionswere
collected at 0◦C according to the scheme in Figure 1.
In all perfusion experiments, the ﬁrst 20min fraction
served to compare catecholamine releases among various
perfusion experiments. The eﬀects of tyramine (10−6 mol/L)
and desipramine (10−7 mol/L) on basal and K+-stimulated
releases of norepinephrine from the sliced atria were tested.
Basal release was determined as the catecholamine outﬂow
from the atria perfused with oxygenated Tyrode solution
with pargyline in the second 20min fraction. K+-stimulated
release was taken as norepinephrine output from tissues
stimulated by depolarization with 50mmol/L KCl with a
concomitant reduction of NaCl in the superfusion ﬂuid in
the second fraction. The third fraction was obtained after
perfusion with Tyrode solution and served to check for
consistency of experiments. Then, the perfusion solution
waschangedforTyrodesolution withdesipramine, tyramine
when basal release was tested, or K+-rich solution with these
substances when their eﬀects on stimulated release were
assessed.
In the additional experiments, the tissue slices were
superfused with basal or K+-rich solutions with above-men-
tioned substances added (i.e., tyramine and desipramine) for
2 hours. Before and after the perfusion, tissues were trans-
ferred into pre-weighed test-tubes, centrifuged at 5000×g,
4◦C for 15min, supernatants were discarded, the samples
were weighed and stored at −70◦Cf o rs u b s e q u e n td e t e r -
mination of catecholamine concentration in tissue slices
before and after perfusion. Norepinephrine concentrations4 Experimental Diabetes Research
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Figure 2: Glucose tolerance tests. Response to intraperitoneal administration of glucose (2g/kg) in old diabetic (STZ22) rats and their age-
matched controls (CONT22). Values are means ± SEM (n = 5 per group). (a) Blood glucose concentrations in given time intervals after
glucose administration. (b) Plasma insulin concentrations after the glucose challenge. ∗signiﬁcantly diﬀerent from value in control group
(P<0.05).
Table 1: Body weights, blood glucose concentrations, and plasma insulin levels in diabetic and control female rats.
Months after STZ Blood glucose (mmol/L) Body weight (g) Plasma insulin (ng/mL)
Control (n = 6) STZ (n = 6) Control (n = 6) STZ (n = 6) Control (n = 6) STZ (n = 5)
18 . 7 ± 0.4 23.7 ± 1.4∗ 270 ± 12 195 ± 5∗ 0.81 ± 0.09 0.11 ± 0.02∗
28 . 2 ± 0.5 26.2 ± 2.4∗ 292 ± 8 198 ± 6∗ 1.09 ± 0.15 0.17 ± 0.02∗
48 . 9 ± 0.2 26.6 ± 1.5∗ 315 ± 9 188 ± 4∗ 1.11 ± 0.12 0.14 ± 0.02∗
22 6.2 ± 0.5 8.5 ± 0.8# 350 ± 12 235 ± 10∗# 0.86 ± 0.09 1.08 ± 0.16#
Values are means ± SEM.; STZ: streptozotocin; ∗signiﬁcantly diﬀerent from value in control group (P<0.05); #signiﬁcantly diﬀerent from STZ1 value (P<
0.05).
in the superfusates were determined using radioimmunoas-
say ultrasensitive diagnostic kits (LDN, FRG).
2.8. Solutions and Chemicals. The composition of the Tyrode
solution was following (in mmol/L): NaCl 137, KCl 4.5,
MgCl2 1, CaCl2 2, glucose 10, Hepes 5; pH was adjusted to
7.4 with 1mol/L NaOH. Metipranolol was from Hoechst-
Biotika, Martin, Slovac Republic. Atropine, streptozotocin,
tyramine hydrochloride, desipramine hydrochloride were
purchased from Sigma Aldrich (Prague, Czech Republic).
Other chemicals were from Lachema (Brno, Czech Repub-
lic). All chemicals were of analytical grade.
2.9. Data Analysis. Results are presented as means ± SEM.
Statistical diﬀerences were tested by unpaired two-tailed
Student’s t-test or by analysis of variance (ANOVA) followed
by post hoc Fisher’s Least Signiﬁcant Diﬀerence test, using
software package STATISTICA Cz, version 7 (StatSoft, Inc.,
Tulsa, OK, USA). Normality of populations and homogene-
ity of variances were tested before each ANOVA. The results
were considered signiﬁcantly diﬀerent when P<0.05.
3. Results
3.1. General. Prior to STZ administration, there were no
signiﬁcant diﬀerences in the body weights, blood glucose
levels, and plasma insulin concentrations between the ani-
mals subjected to STZ or vehicle injection. When compared
to controls, body weights, plasma and pancreatic insulin
levels were signiﬁcantly lower (P<0.01), and blood
glucose concentrations signiﬁcantly higher in diabetic rats
1, 2, and 4 months after STZ administration (Table 1).
Interestingly, animals 22 months after STZ administration
displayed symptoms of partial spontaneous recovery having
blood glucose and plasma insulin levels not diﬀering from
age-matched controls. However, body weights remained
signiﬁcantly lower than in the age-matched controls (P<
0.05) and their glucose tolerance was markedly impaired as
shown in Figure 2.
In all samples processed by immunohistochemistry, the
pancreata were well preserved, without autolysis and islets
showed no signs of either ﬂorid inﬂammation or lympho-
cytes/macrophages inﬁltration. Typical histological ﬁndings
are summarized in Figure 3. Quantitative analysis of theExperimental Diabetes Research 5
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Figure 3: Expression of pancreatic insulin detected by immunohistochemistry in representative micrographs of a young healthy rat (a), a
diabetic rat 1 month after STZ administration (b), an old healthy rat (c), and an old diabetic rat 22 months after STZ administration (d).
In (a), the islets were rich in insulin-positive cells; also the intensity of reaction was very strong. In (b), the islets (red-dashed outline) were
small and contained only traces of insulin positivity (green arrow). The overall shrinkage of islet mass and depopulation of beta cells in
group were accompanied by islet reorganization, impairing the natural structure of endocrine trabecular epithelium. In (c), the islets were of
normal size, while the insulin-positive cells occupied most of the islets. In (d), the islets showed signs of tissue remodelling when compared
with control rats, but they contained population of insulin-positive cells similar to the pancreata of healthy animals of comparable age. Scale
bar indicates 50μm.
selected pancreatic samples indicated that volume fraction
of insulin-positive cells within the pancreas Vv(insulin,
pancreas) of CONT22 rats was 0.15 ± 0.01%, which was
signiﬁcantly higher than in STZ1 rats (0.02 ± 0.01%;
P<0.05). In STZ22 samples, volume fraction of insulin-
positive cells reached the value 0.08 ± 0.03%, that is,
higher than in STZ1 rats, but still lower than in CONT22
pancreata.
3.2. Eﬀect of Metipranolol after Atropine Pretreatment on
the Heart Rate. As shown in Table 2, STZ-diabetic females
displayedsigniﬁcantrestingbradycardiafromtheﬁrstmonth
after the onset of the disease with a trend to further reduce
the heart rate with the disease duration. In addition, resting
bradycardia was accompanied with an almost complete
loss of the sympathetic nervous tone to the heart. Partial
spontaneous recovery of diabetes at the age of 2 years led
to full restoration of the sympathetic tone; however, resting
bradycardia was still considerable and the spontaneous
beatingrateoftheisolatedheartatriawastheslowestinthese
aged STZ-diabetic animals compared to all younger diabetic
and age-matched control rats (Figure 5). Thus, in spite of
betterdiabetescompensation,thefunctionofsinoatrialnode
further worsened in the course of experiment.
3.3. Norepinephrine Concentrations in the Heart Atria of
Control and Diabetic Rats. In the control rats at the age
of 3 months, norepinephrine concentrations were 1731 ±
142ng/g and 1550 ± 115ng/g in the right and left atria;
respectively, and they did not change signiﬁcantly with
age. The diabetic state led to a slight, but signiﬁcant,
increase in atrial norepinephrine levels 1 month after STZ
administration. In STZ2 and STZ4 rats, norepinephrine
concentrations in both atria did not signiﬁcantly diﬀer from
the respective controls although they displayed declining
trendcomparedtoSTZ1animals.Incontrast,STZ22ratshad
atrial tissue concentrations of norepinephrine by ∼30–40%
higher than the age-matched controls (Figure 4).6 Experimental Diabetes Research
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Figure 4: Norepinephrine concentrations in the right (a) and left (b) atria of STZ-diabetic rats 1, 2, 4, and 22 months after STZ
administration and their respective controls. Data are means ± SEM; ∗P<0.05 compared to the respective control; +P<0.05 compared to
STZ1 value.
Table 2: Resting heart rate and the eﬀect of metipranolol after atropine administration on the heart rate in diabetic and control female rats.
Months after STZ Resting heart rate (min−1)E ﬀect of MP after ATR (min−1)
Control (n = 6) STZ (n = 6) Control (n = 6) STZ (n = 5)
1 345 ± 8 280 ± 6∗ −122 ± 7 −10 ± 8∗
2 352 ± 9 252 ± 7∗ −130 ± 8 −8 ± 5∗
4 355 ± 7 238 ± 7∗ −92 ± 5 −1 ± 5∗
22 345 ± 10 309 ± 11∗ −116 ± 9 −105 ± 11#
Values are means ± SEM; STZ: streptozotocin; MP: metipranolol; ATR: atropine; ∗signiﬁcantly diﬀerent from value in control group (P<0.05); #signiﬁcantly
diﬀerent from STZ1 value P<0.05.
3.4. Evaluation of Tyramine-Induced Positive Chronotropic
Eﬀect. The spontaneous beating rate of the isolated right
atrium in tyramine-free solution was signiﬁcantly lower in
diabetic rats compared to control ones in all age categories.
The beating rate in control groups decreased with age to
values signiﬁcantly lower in CONT22 samples as against
all younger age categories reaching 216 ± 11beats/min in
CONT1 and 186 ± 6b e a t s / m i ni nC O N T 2 2a t r i a .T h i st i m e -
dependent decrease in the spontaneous beating rate was yet
more pronounced in diabetic rats, where it was signiﬁcantly
lower in partially compensated diabetic rats compared
to younger STZ groups reaching 166 ± 4beats/min in
STZ1 samples and 117 ± 1 0 b e a t s / m i ni nS T Z 2 2o n e s
(Figure 5).
In both control and diabetic groups, tyramine (stim-
ulator of norepinephrine release via inversely working
norepinephrine transporter) exerted the dose-dependent
positive chronotropic eﬀect on the spontaneous beating
rate of the right atrium. The dose-related increment in
the pacemaker discharge rate was comparable in all control
groups (Figure 5). In uncompensated diabetic groups, the
concentration dependent chronotropic eﬀect of tyramine
did not show any important diﬀerence compared to age-
matched controls; beating rate in STZ1, STZ2, and STZ4 at
tyramine concentration of 10−4 mol/L was by ∼35% higher
compared to the rate in tyramine-free solution (Figures 5(a),
5(b),a n d5(c)). In contrast, the isolated atria of partially
compensated rats displayed a steep increase in sensitivity to
chronotropic eﬀect of tyramine; discharge rate in STZ22 at
tyramine concentrations from 10−6 to 10−4 mol/L did not
diﬀer from age-matched controls (Figure 5(d)).
3.5. Release of Norepinephrine from the Heart Atria. Basal
release of norepinephrine from the control atria was 450
± 35pg/g/min and it was not signiﬁcantly aﬀected by the
age of animals, being 348 ± 42pg/g/min, in CONT22 rats.
Basal norepinephrine release from the atrial preparations
of diabetic rats did not diﬀer from the respective control
values. Norepinephrine release evoked by depolarization
with high KCl concentration was increased in STZ1, STZ2,Experimental Diabetes Research 7
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Figure 5: The eﬀect of tyramine on the spontaneous beating right atria in control and diabetic (STZ-) rats 1 (a), 2 (b), 4 (c) and 22 (d)
months after STZ or vehicle application. Open squares—control rats (n = 5 in (a, (b),and (c)), n = 4 in (d), ﬁlled squares—diabetic rats
(n = 5i np a n e l sa ,b ,a n dc ,n = 4 in panel d). ∗signiﬁcantly diﬀerent from control rats (P<0.05).
and STZ4 atria when compared to the respective con-
trols. In contrast, STZ22 samples displayed KCl-evoked
norepinephrine release not diﬀering from the control
preparations (Figure 6(a)). Tyramine signiﬁcantly enhanced
basal norepinephrine release from both control and dia-
betic atria; however, in STZ4 samples it was signiﬁcantly
lower than that in STZ1 ones (Figure 6(b)). Desipramine,
blocker of neuronal norepinephrine transporter, had no
signiﬁcant eﬀect on basal norepinephrine overﬂow from
both control and STZ-treated rat heart atria (data not
shown). In contrast, it enhanced KCl-evoked release in all
control preparations and STZ1, STZ2, and STZ22 atria,
but inhibited the same parameter in STZ4 atrial prepara-
tions (Figure 6(c)). Tyramine in KCl-rich solution further
increased norepinephrine output in all samples; however, its
eﬀect seemed to be relatively smaller in the diabetic rats 1,
2, and 4 months after the onset of diabetes and greater in
STZ22 atria (Figure 6(d)). Nevertheless, when expressed in
absolutevalues,therewerenosigniﬁcantdiﬀerencesbetween
tyramin-induced eﬀects in K+-rich solution between control
and diabetic preparations with exception of the STZ22
samples.
3.6. Concentration of Norepinephrine in the Atrial Slices before
and after Perfusion. To evaluate the releasable pool of nore-
pinephrine in the heart atria, norepinephrine concentrations
were measured in the sliced samples before and after the
perfusion experiment. In the control samples and in all
youngdiabeticgroups(STZ1,STZ2,andSTZ4),theeﬀectsof
individualinterventionsontherelativenorepinephrinelevels
in the tissue after perfusion did not signiﬁcantly diﬀer. Both
tyramine and KCl depleted the norepinephrine contents to
similar extent (∼50%) and their combination to even ∼30%.
In contrast, tyramine alone depleted norepinephrine from
STZ22 tissue slices by 62% and high K+ concentration with
tyramine even by 84% (Figure 7).
4. Discussion
The present study addressed the impact of short- and long-
term diabetes on norepinephrine release and uptake in the8 Experimental Diabetes Research
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Figure 6: Norepinephrine release from the sliced heart atria of control and diabetic (STZ) rats 1, 2, 4, and 22 months after STZ or vehicle
application (CONT1, CONT2, CONT4, and CONT22 and STZ1, STZ2, STZ4, and STZ22, resp.). Data are means ± SEM; ∗P<0.05
compared to the respective control; +P<0.05 compared to STZ1 value.
heart atria of female rats aged 3 months to 2 years in
relation to functional parameters, that is, the tonic inﬂuence
of the sympathetic nervous system on the heart rate and
chronotropic response of the isolated atria to tyramine-
stimulated norepinephrine release.
As expected, diabetic state induced by STZ was asso-
ciated with severe hyperglycemia and hypoinsulinemia and
low insulin positivity in the pancreas of rats 1, 2, or 4
months after STZ administration. However, at the age of
2 years, surviving diabetic animals displayed symptoms of
partial spontaneous recovery with normal blood glucose
and plasma insulin levels, but impaired glucose tolerance.
Volume fraction of insulin-positive cells within the pancreas
in partially compensated rats was higher than that in
uncompensated diabetic animals, but still lower than that
in the respective controls. We have already reported this
interesting feature of STZ-induced diabetes in female rats at
the age of 14 months when about 30% of animals displayedExperimental Diabetes Research 9
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Figure 7: Concentrations of norepinephrine in tissue slices of
the heart atria of control and STZ-diabetic rats at the age of 2
years (CONT22 and STZ22, resp.) after the perfusion experiments
without (nil) or with releasing substances added. The data are
expressed in % of the respective concentration before perfusion.
Tyr: tyramine, Des: desipramine; ∗signiﬁcantly diﬀerent from
control samples (P<0.05).
regeneration of the insulin-secreting tissue [11]. This study
shows that with advancing age, all surviving diabetic animals
seemed to recover incompletely from STZ-induced damage
to pancreatic B cells; nevertheless, their response to glucose
load did not result in any clear improvement in insulin
secretion. The spontaneous partial recovery from STZ-
induced diabetic state has been proved also in newborn rats
[12] and in adult rats treated by low doses of STZ [13]. The
sensitivity to STZ may be also inﬂuenced by gender—the
lower susceptibility to diabetogenic eﬀect of STZ has been
found in female [14] and castrated male mice [15]c o m p a r e d
to uncastrated males.
Our study also indicated that the resting heart rate
and sympathetic tone were not markedly aﬀected in female
control rats till the age of two years. In contrast, diabetic
animals displayed resting bradycardia that could be at least
partly attributed to almost complete disappearance of the
sympathetic tone from the ﬁrst month of the disease. Similar
ﬁndings were reported in diabetic male rats 1 to 14 weeks
after STZ administration [16]. Interestingly, in spite of full
recoveryofthesympathetictoneinolddiabeticrats(STZ22),
the resting heart rate remained signiﬁcantly lower than
that in the age-matched controls suggesting direct diabetes-
induced damage to the sinoatrial node. Analysis of the
spontaneous beating rate of the right atrium isolated from
aging control and diabetic rats showed that the function
of sinoatrial pacemaker declined with age, and this trend
was further accentuated by diabetes. The age-dependent
changes in the node could result from electrophysiological
disturbances, degenerative changes of the myocardium or
of restriction of pacemaker cells [17–20]. Regional defect in
the expression and/or electrophysiology of ion channels and
the structural remodeling of gap junction connexin proteins
found in the STZ-treated rats may underlie dysfunction of
the sinoatrial node and bradycardia in the experimental
insulin-dependent diabetes mellitus [21, 22]. In addition,
the alteration of heart rate and pacemaker dysfunction
are known to be risk factors of arrhythmias observed in
diabetic patients [23]. Gender diﬀerences in the propensity
for various types of cardiac arrhythmias in nondiabetic
population [24, 25] and experimental animals [26]a r ew e l l
recognized. Putative gender-speciﬁc impact on susceptibility
to arrhythmias in long-standing STZ diabetes remains to be
precisely determined.
Assessment of parameters of the cardiac sympathetic
innervation at the level of eﬀector organ showed an increase
in norepinephrine concentrations in the heart atria 1 month
after the onset of diabetes followed by a decrease later,
which is in good agreement with previous studies on male
and female rats [11, 27–29]. The initial increase in the
cardiac norepinephrine levels could be attributed to diﬀerent
mechanisms that have been reported in several studies
on rats 4–12 weeks after administration of a diabetogenic
STZ dose: increased synthesis of norepinephrine, due to
the enhanced activity of tyrosine hydroxylase [8], increased
uptake of norepinephrine by adrenergic nerve terminals [30]
or its diminished calcium-dependent exocytotic release [31].
However, all these data were collected on relatively young
male rats. Reports dealing with the impact of age on gender-
speciﬁc features of the cardiovascular adrenergic innervation
suggest multiple diﬀerences in exocytotic release, uptake,
metabolism, and norepinephrine sensitivity between males
and females: whereas, in males, cardiac norepinephrine con-
centration,release,uptake,andturnoverratewererepeatedly
reported to be decreased with advancing age, females seemed
to be more resistant to these changes [32, 33]. Our study
also documents that till the age of 2 years, norepinephrine
concentrations in the atria, neurotransmitter release, and
uptake remained comparable between young- and old- age
female categories.
The results of the present study also documented that
exocytotic release tested as K+-evoked norepinephrine out-
ﬂow from the sliced atria was enhanced in all uncom-
pensated STZ-diabetic female rats (i.e., STZ1, STZ2, and
STZ4) rats in contrast to previously described attenuation
of norepinephrine exocytosis in the male atria 8 to 12
weeks after the onset of diabetes [31]. It should be noted
that calcium dependency of K+-evoked release could be
modiﬁed by diabetes. In one of our previous studies,
an increased contribution of calcium-independent, that is,
carrier-mediated nonexocytotic mechanism to K+-evoked
norepinephrine release was documented [34]. Therefore,
we studied the eﬀects of norepinephrine transporter sub-
strate tyramine and its blocker desipramine on both basal
and stimulated releases. The results of these experiments
suggest that in the ﬁrst two months of severe diabetes,
norepinephrine transporter function was not signiﬁcantly
aﬀected. However, 4 months after the onset of diabetes,
both tyramine and desipramine eﬀects were signiﬁcantly
smaller than that in younger diabetics, even if expressed
in absolute values. Tyramine enters the nerve ending via10 Experimental Diabetes Research
norepinephrine transporter, replaces norepinephrine in the
cytoplasm, and via monoamine vesicular transporter also
in the synaptic vesicles. Increased cytoplasmic concentration
of norepinephrine then causes reversal of norepinephrine
transport across the cell membrane [35]. Lower eﬀect of
tyramine could be related to the impaired function of
norepinephrine transporter or compromised tissue stores
of releasable norepinephrine. Indeed, in the diabetic male
rats, 4 weeks of STZ-diabetes were suﬃcient to induce
substantial reduction in norepinephrine transporter expres-
sion in the heart [36]. Diminished eﬀect of desipramine
could be explained by decreasing activity or density of the
neuronal carrier [37]. However, this interpretation might
be misleading in case of substantial changes in conditions
inﬂuencing transporter aﬃnity and direction of action [38]
that could be inversed by an enhanced intracellular concen-
tration of norepinephrine or sodium ions [31, 39, 40]. Both
decreased activity of Na+-, K+-ATPase leading to decrease
in the transmembrane sodium concentration gradient and
defective vesicular transport of norepinephrine resulting in
the increased cytosolic norepinephrine concentrations were
suggested in STZ-diabetic hearts [31, 41]. Whatever were
the mechanisms underlying diminishing eﬀects of tyramine
anddesipramineonnorepinephrinereleasefromthediabetic
atria, tyramine-induced increases in the atrial beating rate
were comparable in all uncompensated STZ groups (i.e.,
STZ1, STZ2, and STZ4), thus implying well-balanced sen-
sitivity of the target tissue to the neurotransmitter released.
The most interesting data were obtained from rats
22 months after STZ administration. They indicated that
sympathetic tonic inﬂuence on the heart rate was fully
restored with partial compensation of diabetes and that
depolarization-induced release of norepinephrine was well
preserved in spite of the long-term disease duration.
Enhanced tyramine-induced release along with the highest
eﬀect of tyramine on the beating rate of the isolated
right atria and striking alterations to norepinephrine atrial
concentrations before and after perfusion indicated change
in the releasable pool of norepinephrine in the nerve
endings.
5. Conclusion
Taken together, our data show that female diabetic heart
seems to be more resistant to diabetes-induced alteration
in adrenergic neurotransmission than the male one—
exocytotic K+-induced release from the heart atria was
well preserved till 4 months of diabetes duration. Slight
decliningtrendcouldbeobservedincarrier-mediatedrelease
of norepinephrine; however, reactivity of the isolated right
atria to tyramine was not altered with age and disease
duration. In spite of this relatively well-preserved parameters
of adrenergic neurotransmission at the level of eﬀector
organ, the tonic sympathetic inﬂuence on the heart rate was
nearly negligible even at the ﬁrst month of diabetes, and the
sinoatrial beating rate also displayed symptoms of gradually
deteriorating function. Partial compensation of diabetes led
to fully recovered sympathetic tone and putative change in
releasable norepinephrine tissue stores.
Conﬂict of Interests
The authors declare that they have no conﬂict of interests.
Acknowledgments
The present study was supported by the Research project
MSM 0021620819: Replacement of and Support to Some
Vital Organs awarded by the Ministry of Education, Youth
and Sports of the Czech Republic. J. ˇ Sv´ ıglerov´ a and J. Mudra
contributed equally to the study.
References
[1] A. I. Vinik, R. Freeman, and T. Erbas, “Diabetic autonomic
neuropathy,” Seminars in Neurology, vol. 23, no. 4, pp. 365–
372, 2003.
[2] D. W. Bergner and J. J. Goldberger, “Diabetes mellitus and
sudden cardiac death: what are the data?” Cardiology Journal,
vol. 17, no. 2, pp. 117–129, 2010.
[3] J. Hilsted, “Catecholamines and diabetic autonomic neuropa-
thy,” Diabetic Medicine, vol. 12, no. 4, pp. 296–297, 1995.
[4] E. Heyman, P. Delamarche, P. Berthon et al., “Alteration in
sympathoadrenergic activity at rest and during intense exer-
cise despite normal aerobic ﬁtness in late pubertal adolescent
girls with type 1 diabetes,” Diabetes and Metabolism, vol. 33,
no. 6, pp. 422–429, 2007.
[5] M. Esler, G. Jennings, G. Lambert, I. Meredith, M. Horne, and
G. Eisenhofer, “Overﬂow of catecholamine neurotransmitters
to the circulation: source, fate, and functions,” Physiological
Reviews, vol. 70, no. 4, pp. 963–985, 1990.
[6] G. Eisenhofer, M. D. Esler, H. S. Cox et al., “Diﬀerences in
the neuronal removal of circulating epinephrine and nore-
pinephrine,” JournalofClinicalEndocrinology andMetabolism,
vol. 70, no. 6, pp. 1710–1720, 1990.
[7] D. S. Goldstein, R. O. Cannon, A. Quyyumi et al., “Regional
extraction of circulating norepinephrine, DOPA, and dihy-
droxyphenylglycol in humans,” Journal of the Autonomic
Nervous System, vol. 34, no. 1, pp. 17–36, 1991.
[ 8 ]P .K .G a n g u l y ,K .S .D h a l l a ,a n dI .R .I n n e s ,“ A l t e r e d
norepinephrine turnover and metabolism in diabetic car-
diomyopathy,” Circulation Research, vol. 59, no. 6, pp. 684–
693, 1986.
[9] P. W. F. Wilson, “Diabetes mellitus and coronary heart
disease,” American Journal of Kidney Diseases, vol. 32, no. 5,
supplement 3, pp. S89–S100, 1998.
[10] H. Colhoun, “Coronary heart disease in women: why the
disproportionate risk?” Current Diabetes Reports,v o l .6 ,n o .1 ,
pp. 22–28, 2006.
[11] J. Kuncov´ a, J. ˇ Sv´ ıglerov´ a, Z. Tonar, and J. Slav´ ıkov´ a, “Het-
erogenous changes in neuropeptide Y, norepinephrine and
epinephrine concentrations in the hearts of diabetic rats,”
Autonomic Neuroscience, vol. 121, no. 1–2, pp. 7–15, 2005.
[12] A. Garofano, P. Czernichow, and B. Breant, “Impaired β-cell
regeneration in perinatally malnourished rats: a study with
STZ,” The Federation of American Societies for Experimental
Biology Journal, vol. 14, no. 15, pp. 2611–2617, 2000.
[ 1 3 ]E .N .S u ,V .A .A l d e r ,D .Y .Y u ,P .K .Y u ,S .J .C r i n g l e ,a n d
K. Yogesan, “Continued progression of retinopathy despite
spontaneous recovery to normoglycemia in a long-term study
of streptozotocin-induced diabetes in rats,” Graefe’s Archive for
Clinical and Experimental Ophthalmology, vol. 238, no. 2, pp.
163–173, 2000.Experimental Diabetes Research 11
[14] A. A. Rossini, R. M. Williams, M. C. Appel, and A. A. Like,
“Sex diﬀerences in the multiple-dose streptozotocin model of
diabetes,” Endocrinology, vol. 103, no. 4, pp. 1518–1520, 1978.
[15] E. H. Leiter, “Multiple low-dose streptozotocin-induced
hyperglycemia and insulitis in C57BL mice: inﬂuence of
inbred background, sex, and thymus,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 79, no. 2, pp. 630–634, 1982.
[16] K. K. Hicks, E. Seifen, J. R. Stimers, and R. H. Kennedy,
“Eﬀects of streptozotocin-induced diabetes on heart rate,
blood pressure and cardiac autonomic nervous control,”
Journal of the Autonomic Nervous System,v o l .6 9 ,n o .1 ,p p .
21–30, 1998.
[17] A. M. W. Alings and L. N. Bouman, “Electrophysiology of the
ageing rabbit and cat sinoatrial node: a comparative study,”
European Heart Journal, vol. 14, no. 9, pp. 1278–1288, 1993.
[ 1 8 ]H .D o b r z y n s k i ,M .R .B o y e t t ,a n dR .H .A n d e r s o n ,“ N e w
insights into pacemaker activity: promoting understanding of
sick sinus syndrome,” Circulation, vol. 115, no. 14, pp. 1921–
1932, 2007.
[19] S. A. Jones, M. R. Boyett, and M. K. Lancaster, “Declining into
failure: the age-dependent loss of the L-type calcium channel
within the sinoatrial node,” Circulation, vol. 115, no. 10, pp.
1183–1190, 2007.
[20] D. D. Christou and D. R. Seals, “Decreased maximal heart rate
with aging is related to reduced β-adrenergic responsiveness
but is largely explained by a reduction in intrinsic heart rate,”
Journal of Applied Physiology, vol. 105, no. 1, pp. 24–29, 2008.
[21] F. C. Howarth, N. Nowotny, E. Zilahi, M. A. El Haj,
and M. Lei, “Altered expression of gap junction connexin
proteins may partly underlie heart rhythm disturbances in
the streptozotocin-induced diabetic rat heart,” Molecular and
Cellular Biochemistry, vol. 305, no. 1–2, pp. 145–151, 2007.
[22] C. F. Howarth, R. Al-Sharhan, A. Al-Hammadi, and M. A.
Qureshi,“Eﬀectsofstreptozotocin-induceddiabetesonaction
potentials in the sinoatrial node compared with other regions
of the rat heart,” Molecular and Cellular Biochemistry, vol. 300,
no. 1–2, pp. 39–46, 2007.
[23] B. Linnemann and H. U. Janka, “Prolonged QTc interval and
elevated heart rate identify the type 2 diabetic patient at high
risk for cardiovascular death. The Bremen diabetes study,”
Experimental and Clinical Endocrinology and Diabetes, vol.
111, no. 4, pp. 215–222, 2003.
[24] J. A. Larsen and A. H. Kadish, “Eﬀects of gender on cardiac
arrhythmias,” Journal of Cardiovascular Electrophysiology, vol.
9, no. 6, pp. 655–667, 1998.
[25] T. V. Pham and M. R. Rosen, “Sex, hormones, and repolar-
ization,” Cardiovascular Research, vol. 53, no. 3, pp. 740–751,
2002.
[26] J. Cheng, “Evidences of the gender-related diﬀerences in
cardiac repolarization and the underlying mechanisms in dif-
ferent animal species and human,” Fundamental and Clinical
Pharmacology, vol. 20, no. 1, pp. 1–8, 2006.
[27] S. Y. Felten, R. G. Peterson, P. A. Shea, H. R. Besch Jr.,
a n dD .L .F e l t e n ,“ E ﬀects of streptozotocin diabetes on the
noradrenergic innervation of the rat heart: a longitudinal
histoﬂuorescence and neurochemical study,” Brain Research
Bulletin, vol. 8, no. 6, pp. 593–607, 1982.
[28] T. Yoshida, H. Nishioka, Y. Nakamura, and M. Kondo,
“Reduced noradrenaline turnover in streptozotocin-induced
diabetic rats,” Diabetologia, vol. 28, no. 9, pp. 692–696, 1985.
[29] N. Akiyama, K. Okumura, Y. Watanabe et al., “Altered
acethlcholine and norepinephrine concentrations in diabetic
rat hearts. Role of parasympathetic nervous system in diabetic
cardiomyopathy,” Diabetes, vol. 38, no. 2, pp. 231–236, 1989.
[30] P.K.Ganguly,R.E.Beamish,K.S.Dhalla,I.R.Innes,andN.S.
Dhalla, “Norepinephrine storage, distribution, and release in
diabetic cardiomyopathy,” American Journal of Physiology, vol.
252, no. 6, pp. E734–E739, 1987.
[31] S. Gando, Y. Hattori, and M. Kanno, “Altered cardiac adren-
ergic neurotransmission in streptozotocin-induced diabetic
rats,”BritishJournalofPharmacology,vol.109,no.4,pp.1276–
1281, 1993.
[ 3 2 ]D .L .S n y d e r ,V .J .A l o y o ,W .W a n g ,a n dJ .R o b e r t s ,“ I n ﬂ u e n c e
of age and dietary restriction on norepinephrine uptake into
cardiac synaptosomes,” Journal of Cardiovascular Pharmacol-
ogy, vol. 32, no. 6, pp. 896–901, 1998.
[33] Y. Takenouchi, T. Kobayashi, K. Taguchi, T. Matsumoto, and
K. Kamata, “Gender diﬀerences in vascular reactivity of aortas
from streptozotocin-induced diabetic mice,” Biological and
Pharmaceutical Bulletin, vol. 33, no. 10, pp. 1692–1697, 2010.
[34] J. Kuncov´ a, J. Slav´ ıkov´ a, and J. ˇ Sv´ ıglerov´ a, “Norepinephrine
release in the heart atria of diabetic rats,” General Physiology
and Biophysics, vol. 22, no. 3, pp. 397–410, 2003.
[35] U. Trendelenburg, “Carrier-mediated outward transport of
noradrenaline from adrenergic varicosities,” Polish Journal of
PharmacologyandPharmacy,vol.42,no.6,pp.515–520,1990.
[36] Y. Kiyono, S. Kajiyama, H. Fujiwara, N. Kanegawa, and H.
Saji, “Inﬂuence of the polyol pathway on norepinephrine
transporter reduction in diabetic cardiac sympathetic nerves:
implications for heterogeneous accumulation of MIBG ,”
European Journal of Nuclear Medicine and Molecular Imaging,
vol. 32, no. 8, pp. 993–997, 2005.
[37] C. Zugck, D. Lossnitzer, J. Backs, A. Kristen, R. Kinscherf,
and M. Haass, “Increased cardiac norepinephrine release in
spontaneously hypertensive rats: role of presynaptic alpha-
2A adrenoceptors,” Journal of Hypertension,v o l .2 1 ,n o .7 ,p p .
1363–1369, 2003.
[ 3 8 ]D .R i c h a r d t ,A .D e n d o r f e r ,R .T ¨ olg, P. Dominiak, and G.
Richardt, “Inhibition of nonexocytotic norepinephrine release
by desipramine reduces myocardial infarction size,” Canadian
Journal of Physiology and Pharmacology, vol. 84, no. 11, pp.
1185–1189, 2006.
[39] A. Langeloh, H. Bonisch, and U. Trendelenburg, “The mech-
anism of the 3H-noradrenaline releasing eﬀect of various
substrates of uptake1: multifactorial induction of outward
transport,” Naunyn-Schmiedeberg’s Archives of Pharmacology,
vol. 336, no. 6, pp. 602–610, 1987.
[40] G. Levi and M. Raiteri, “Carrier-mediated release of neuro-
transmitters,” Trends in Neurosciences, vol. 16, no. 10, pp. 415–
419, 1993.
[41] V. Javorkov´ a, L. M´ ezeˇ sov´ a, J. Vlkoviˇ cov´ a, and N. Vrbjar,
“Inﬂuence of sub-chronic diabetes mellitus on functional
properties of renal Na(+),K(+)-ATPase in both genders of
rats,”GeneralPhysiologyandBiophysics,vol.29,no.3,pp.266–
274, 2010.